Pelthos Therapeutics Inc. (PTHS) - 10-K Summary
Business Context and Reporting Period
Reporting Period: Fiscal year ended December 31, 2025.
Corporate Structure: Pelthos Therapeutics Inc. was effectively formed on July 1, 2025, via a merger between Channel Therapeutics Corporation and LNHC, Inc. (a subsidiary of Ligand Pharmaceuticals). The company is an emerging growth company and smaller reporting company.
Core Business: A bio-pharmaceutical company focused on commercializing dermatology products. The portfolio includes:
- ZELSUVMI (berdazimer): FDA-approved topical gel for molluscum contagiosum, launched in July 2025.
- XEPI (ozenoxacin): Acquired in November 2025 for the treatment of impetigo; relaunch expected in late 2026.
- XEGLYZE (abametapir): Acquired in December 2025 for the treatment of head lice; launch expected in 2027.
- Pipeline: Clinical-stage NaV1.7 pain programs (Eye Pain, Depot, Neuropathic Pain).
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | Value (in thousands) |
|---|---|
| Total Revenue | $16,795 |
| Net Product Revenue | $16,206 |
| Operating Expenses | $49,225 |
| Net Loss | $(43,319) |
| Cash and Cash Equivalents (Dec 31, 2025) | $17,973 |
| Working Capital | $27,417 |
| Convertible Debt (Fair Value) | $31,441 |
| Long-Term Liabilities (Royalty/Reedy Creek) | $30,050 |
Note: Revenue reflects approximately six months of commercial activity for ZELSUVMI following the July 2025 launch.
Material Changes vs. Prior Period
- Revenue Generation: The company transitioned from $0 revenue in 2024 to $16.8 million in 2025, driven by the commercial launch of ZELSUVMI.
- Expense Surge: Operating expenses increased from $7.6 million in 2024 to $49.2 million in 2025. This includes a $36.1 million increase in SG&A due to the build-out of the commercial sales force (approx. 53 territory managers) and marketing infrastructure.
- Acquisitions: The company acquired XEPI and XEGLYZE in Q4 2025, adding significant intangible assets ($6.1M and $1.8M respectively) and contingent liabilities.
- Financing Activity:
- Completed a PIPE financing in July 2025 raising approx. $50.1 million gross proceeds (net proceeds approx. $27.4 million after settlements).
- Issued $18.0 million in Convertible Notes in November 2025.
- Secured a $50.0 million senior secured term loan facility in January 2026, drawing $30.0 million immediately.
- Going Concern: The 2024 audit contained a going concern qualification. The 2025 audit does not contain this qualification, as management believes current capital and cash flows are sufficient for the next 12 months.
Guidance, Outlook, and Risks
Outlook: Management expects to continue incurring significant operating losses until ZELSUVMI revenue is sufficient to fund operations. The company is focused on scaling ZELSUVMI sales and preparing for the relaunch of XEPI (late 2026) and XEGLYZE (2027).
Key Risks:
- Commercial Execution: Heavy dependence on the commercial success of ZELSUVMI. Failure to achieve market acceptance or reimbursement could impair viability.
- Liquidity: While the going concern qualification was removed, the company remains cash-burn heavy and dependent on future financing or revenue growth to sustain operations long-term.
- Intellectual Property & Licensing: The company relies on in-licenses from Ligand for ZELSUVMI (NITRICIL technology). Ligand retains rights to the IP portfolio and may terminate the license if specific commercialization milestones in Europe are not met by 2026/2027.
- Debt Obligations: Significant royalty obligations (Reedy Creek, Ligand, NRV, Madison) and Convertible Notes create substantial future cash flow requirements. The Convertible Notes were recorded at fair value, resulting in a $14.9 million non-cash loss in 2025 due to fair value adjustments.
- Seasonality: ZELSUVMI sales are subject to seasonality, with a noted downward impact in Q4 2025 due to holidays and weather.
Investor Verification Checklist
- Revenue Sustainability: Verify the trajectory of ZELSUVMI net product sales and the impact of gross-to-net adjustments (rebates, co-pay assistance) on net revenue.
- Debt Covenants & Milestones: Review the specific milestones required to draw the remaining $20 million of the Horizon Technology Finance loan and the terms of the Convertible Notes (conversion price, default triggers).
- License Termination Risks: Confirm the status of the Ligand license agreement, specifically the deadlines for commercializing ZELSUVMI in France, Germany, Italy, Spain, and the UK (Sept 2026 / March 2027).
- Acquisition Integration: Assess the timeline and costs associated with the relaunch of XEPI and XEGLYZE, including supply chain validation and regulatory filings.
- Customer Concentration: Note that three wholesalers accounted for 89% of gross revenue and 90% of accounts receivable in 2025.